-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, it was announced that the company will be in the near future product line adjustment, mainly related to the following four points: hospital representatives to lay off 200, OTC representatives to increase 400 places, KA to increase 100 places, DM can be transferred to KA; AND and WGL and XLB merger;
it is unclear whether hospital representatives will have the opportunity to transfer to OTC, based on 200 job cuts and an additional 500 jobs, the company's product line adjustment, will be 300 more jobs.
that the company was formally established on the 16th of this month, consisting of a merger of Mylan and Pfizer's business unit Pfizer.
Pfizer is Pfizer's global business group focused on patent expired branded and generic drugs.
from this architectural adjustment, it is not difficult to see that the company will focus on the layout of the OTC area of the market, and this move may be a follow-up to the continuous reduction of drug prices.
the current domestic policy direction, drug price reduction is the general trend.
of the belt will also further radiate throughout the country, forming a price linkage.
market share of generic drugs evaluated by consistent evaluation will increase rapidly in the future, accelerating the replacement of imported raw drugs, and multinational pharmaceutical companies will be hit as a result.
drug price reduction normalization, will certainly let enterprises start to adjust the business layout, so there will still be a large number of employees face "job optimization."
。